1.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ZNTL Giù?
Forum
Previsione
Precedente Chiudi:
$1.51
Aprire:
$1.5
Volume 24 ore:
294.50K
Relative Volume:
0.31
Capitalizzazione di mercato:
$105.77M
Reddito:
-
Utile/perdita netta:
$-292.19M
Rapporto P/E:
-0.3238
EPS:
-4.54
Flusso di cassa netto:
$-208.41M
1 W Prestazione:
+2.08%
1M Prestazione:
+8.89%
6M Prestazione:
-33.78%
1 anno Prestazione:
-65.89%
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Nome
Zentalis Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 263-4333
Indirizzo
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Confronta ZNTL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ZNTL
Zentalis Pharmaceuticals Inc
|
1.47 | 102.89M | 0 | -292.19M | -208.41M | -4.54 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-08-12 | Aggiornamento | Wedbush | Underperform → Neutral |
2024-06-20 | Downgrade | UBS | Buy → Neutral |
2024-06-18 | Downgrade | Jefferies | Buy → Hold |
2024-06-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2024-06-18 | Downgrade | Wedbush | Neutral → Underperform |
2024-06-18 | Downgrade | Wells Fargo | Overweight → Equal Weight |
2023-11-08 | Downgrade | Wedbush | Outperform → Neutral |
2023-11-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
2022-07-12 | Iniziato | Cowen | Outperform |
2022-04-06 | Iniziato | Wells Fargo | Overweight |
2021-10-07 | Ripresa | Jefferies | Buy |
2021-09-30 | Iniziato | Stifel | Buy |
2021-09-29 | Iniziato | Oppenheimer | Outperform |
2021-05-21 | Iniziato | UBS | Buy |
2021-01-20 | Iniziato | Wedbush | Outperform |
2020-09-29 | Iniziato | Cantor Fitzgerald | Overweight |
2020-08-27 | Iniziato | H.C. Wainwright | Buy |
2020-04-28 | Iniziato | Guggenheim | Buy |
2020-04-28 | Iniziato | Jefferies | Buy |
2020-04-28 | Iniziato | Morgan Stanley | Overweight |
2020-04-28 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Zentalis Pharmaceuticals Inc Borsa (ZNTL) Ultime notizie
Is Zentalis Pharmaceuticals Inc. a good long term investmentFree Technical Analysis Support - Autocar Professional
What analysts say about Zentalis Pharmaceuticals Inc. stockFree Stock Selection - Autocar Professional
Zentalis Pharmaceuticals Inc. Stock Analysis and ForecastAccelerated capital growth - Autocar Professional
What drives Zentalis Pharmaceuticals Inc. stock priceExplosive trading opportunities - Autocar Professional
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionPrecision Entry Strategy - Newser
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyHigh Return Investment Tips - Newser
How Zentalis Pharmaceuticals Inc. stock performs during market volatilityDaily Swing Candidates - Newser
Insider Stock Buyers At Zentalis Pharmaceuticals Recouped Some Losses This Week - simplywall.st
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Purchases 33,958 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - TradingView
Zentalis Grants $1.19 Per Share Stock Options Package Under Nasdaq Compliance Rules - Stock Titan
Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) dropped from Russell Small Cap Completeness Index - MarketScreener
Zentalis Pharmaceuticals shareholders elect three directors at annual meeting - Investing.com
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of “Hold” from Brokerages - Defense World
Wealth Enhancement Advisory Services LLC Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Bank of America Corp DE - Defense World
Squarepoint Ops LLC Reduces Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Ameriprise Financial Inc. Purchases New Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies - The Globe and Mail
ProShare Advisors LLC Lowers Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Why Did Zentalis Pharmaceuticals Inc. (ZNTL) Plunge 11.33%? - AInvest
Nuveen Asset Management LLC Has $1.94 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Deutsche Bank AG Grows Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Two Sigma Investments LP Sells 291,801 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zentalis Expands Cancer Research Team: 137K Share Options Granted to Key New Hires - Stock Titan
Zentalis Pharmaceuticals Presents Promising Study Results at ASCO - TipRanks
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Millennium Management LLC - Defense World
Northern Trust Corp Raises Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
BNP Paribas Financial Markets Invests $534,000 in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Captrust Financial Advisors Buys New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Analysts - Defense World
Jane Street Group LLC Boosts Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals at H.C. Wainwright BioConnect Conference - TipRanks
Balyasny Asset Management L.P. Has $175,000 Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World
Wedbush Issues Optimistic Outlook for ZNTL Earnings - Defense World
Wedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Defense World
Zentalis Pharmaceuticals First Quarter 2025 Earnings: US$0.67 loss per share (vs US$0.14 profit in 1Q 2024) - Yahoo Finance
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Zentalis Pharmaceuticals Inc Azioni (ZNTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):